of Diseases Treated by
Treatment of Incurable Diseases of Central Nervous System, Brain and Spinal Cord Injuries, by BCRO Fetal Precursor Cell Transplantation
Parkinson's disease became a landmark in history of the use of fetal precursor cell transplantation when a series of such treatments was carried out in Mexico City in 1980's on a group of patients suffering from an advanced stage of this incurable illness with various degrees of success.
Treatment of diseases of central nervous system by fetal precursor cell transplantation requires implantation into the brain and spinal cord, even though not necessarily into the body of these organs. The implantation can be 'intrathecal', i.e. into the cerebrospinal fluid, a vitally important fluid for the function of central nervous system, which circulates in the preformed spaces around and in the brain and spinal cord.
This is the least traumatic method of neurotransplantation as there is no trauma when cells are implanted via lumbar puncture.
The existing treatments of all degenerative diseases suffer from one common problem: no attempt at regeneration of degenerating cells of diseased organs and tissues is ever made. The sole treatment capable of direct stimulation of regeneration is fetal precursor cell transplantation. That applies primarily to degenerative diseases of central nervous system, all incurable by definition.
Treatment of neurological diseases has always been a sad chapter of medicine due to lack of effective therapy for great majority of diseases.
Here Parkinson's disease has been a bright exception because of availability of levodopa therapy, which controls symptoms of disease quite well for a few years. Ultimately every patient with Parkinson's disease will reach a stage when medications which stimulate production of a neurotransmitter dopamine by neurons of the pertinent part of the brain stop working, whereupon life becomes a pure misery and death will ensue. Ideally, already before that happens, each patient should undergo BCRO fetal precursor cell transplantation.
After Mexico neurotransplantation treatment of Parkinson's disease was carried out in Sweden but with a success rate of 2% only, while under experimental conditions the rate of success was 95. The discrepancy between the high success of neurotransplantation in animal experiment and low success in clinical practice, was unusual that much more that our own clinical success rate has been at all times over 90%.
The first U.S. National Institute of Health clinical trial of Parkinsonís disease treatment ended in a failure. Part of the problem was that researchers were more concerned about fulfilling requirements of double-blind study, including unethical and immoral 'sham surgery', for which the patients still had to pay $ 40,000,-, than to help desperate patients.
Fetal precursor cell transplantation, usually reserved to untreatable or incurable diseases, is hardly suitable for 'double-blind' clinical studies.
When stem cells were found in three different parts of the adult brain, it meant to us that regeneration of damaged brain tissue is possible. This applies to neurons that carry nerve impulses, as well as to supporting glial cells, without which neurons cannot survive.
We treated in 1994-6 over 500 patients with a variety of advanced incurable degenerative diseases of brain and spinal cord, such as Parkinsonís disease, amyotrophic lateral sclerosis, multiple sclerosis, Friedreich's ataxia, various spino-cerebellar degenerations, etc., and lately also patients with old spinal cord injuries, via implantation of BCRO fetal precursor brain cells into the spinal canal.
Here is the simplified classification of incurable diseases of central nervous system, some quite common, others rare, that we treated with BCRO fetal precursor cell transplantation in 1994-6:
- Metachromatic leukodystrophy
- Globoid leukodystrophy or Krabbe disease,
∑ Cancellous marrow degeneration or Canavan disease, or van Bogaert and Bertrand disease,
∑ Sudanophilic leukodystrophies or Pelizeus-Merzbacher disease.
B. Demyelinization diseases:
- Diffuse sclerosis or Schilder encephalitis periaxialis,
∑ Multiple sclerosis,
∑ Neuromyelitis optica or Devic syndrome.
C. Cerebro-ocular degenerations:
- Amaurotic idiocy, infantile form or Tay-Sachs disease
late infantile form or Bielschowsky disease,
juvenile form or Spielmeyer-Vogt disease,
∑ Tapeto-retinal degeneration,
D. Spino-cerebellar degenerations:
- Friedreichís ataxia,
∑ Ataxia-telangiectasia or Louis-Bar syndrome,
∑ Abetalipoproteinemia, Acanthosis, Bassen-Kornzweig syndrome,
∑ Refsum syndrome,
∑ Myoclonus encephalopathy in children, Kinsbourne syndrome.
E. Cerebro-cutaneous degenerations:
- Tuberous sclerosis or Bourneville syndrome,
∑ Neurofibromatosis or v. Recklinghausenís disease,
∑ Angiomatosis retinae et cerebelli or v. Hippel-Lindau disease.
F. Spino-neuro-muscular degenerations:
- Neural muscle atrophies: Wolfrath-Kugelberg-Welander,
∑ Progressive muscle dystrophies: Duchenne,
∑ Myatonia congenita,
∑ Thomsen myatonia,
∑ Carnithine myopathy,
∑ Myasthenia gravis,
Amyotrophic lateral sclerosis,
G. Degeneration of basal ganglia
- Hepatolenticular degeneration or Wilsonís disease,
∑ Dystonia musculorum deformans, Torsion dystonia,
∑ Huntingtonís chorea,
∑ Pigmentary degeneration of globus pallidus or Hallervorden-Spatz syndrome,
∑ Parkinsonís disease.
In another published study of 14 patients in 1994-6, treated by implantation of fetal precursor brain cells into the spinal canal, there was a group of 9 patients that were in deep coma for weeks, due to severe brain hemorrhage, severe head injury, of which two patients (anaphylactic shock after antibiotic injection; general anesthesia mishap during cataract surgery) survived clinical death twice. All 9 patients woke up from coma within 24 hours after BCRO fetal precursor cell transplantation.
We treated by implantation of fetal precursor brain cells during the past 15 years patients with a variety of neurological diseases, for which treatment is not known, such as genetic diseases, injuries, cerebrovascular accidents, etc., or for which treatment had lost its effectiveness in the course of the progression of illness, such as Parkinsonís disease, etc., with initially low success rate. The main reason was a low viability of implanted human fetal precursor brain cells, which have been used 'fresh'..
Once we began to use BCRO method of tissue culture for preparation of fetal precursor brain cells and implanted cell transplants immediately after their release from laboratory, the viability of implanted cells was increased to almost 100% and the clinical results became excellent. To implant dead brain cells is meaningless.
Spinal cord injuries, old or recent, have been considered a supreme challenge in medicine. Prior to July 1, 2005, we have treated 20 patients with old spinal cord injuries with complete transection of spinal cord and 17 of them had an improvement after only one course of intrathecal BCRO fetal precursor cell transplantation, which proved beyond any doubt that neuronal regeneration is possible by our therapeutic approach.
In the clinical trial in Florida ~ 10 years ago 10 patients with Parkinsonís disease received transplantation of fetal neural cells of animal origin in order to eliminate the problem of viability. This trial proved that xeno-neuro-transplantation is tolerated equally well by patients as when human fetal brain cells are implanted. Since 1997 we have used strictly BCRO fetal precursor cells from rabbit fetuses (from closed colony) for intrathecal implantation.
|ABOUT BCRO||WARRANTY/REPLACEMENT||DISCLAIMER||PRIVACY STATEMENT|
|Copyright Stem Cell Transplantation Ltd.|
|Updated: March 2015|